ADC Therapeutics (ADCT) Non-Current Assets (2019 - 2026)
ADC Therapeutics (ADCT) posted Non-Current Assets of $14.7 million for Q1 2026, down 12.41% sequentially from $16.8 million in Q4 2025, and up 1.22% YoY from $14.6 million in Q1 2025.
ADC Therapeutics (ADCT) Non-Current Assets (2019 - 2026) Analysis & Trends
ADC Therapeutics has reported Non-Current Assets for 8 years, with the latest figure at $14.7 million in Q1 2026.
- Quarterly Non-Current Assets rose 1.22% year-over-year to $14.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.0 million (down 52.48% YoY) and the FY2025 annual result came in at $16.8 million, down 45.27% from the prior year.
- Non-Current Assets retreated to $14.7 million in Q1 2026 per ADCT's latest filing, from $16.8 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $96.0 million in Q2 2022 and troughed at $2.6 million in Q3 2025.
- A 5-year average of $45.0 million and a median of $18.5 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets soared 66.17% in 2024, then slumped 83.77% in 2025.
- Over 5 years, Non-Current Assets stood at $55.9 million in 2022, then slumped by 66.91% to $18.5 million in 2023, then jumped by 66.17% to $30.7 million in 2024, then sank by 45.27% to $16.8 million in 2025, then dropped by 12.41% to $14.7 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $14.7 million, $16.8 million, and $2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.33 Bn | 78.34 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.13 Bn | 59.95 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 60.47 Bn | 55.33 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.04 Bn | 27.73 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.48 Bn | 10.09 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.39 Bn | - | 18.06 Bn |
| 10 | ADC Therapeutics | 152.10 Mn | -67.01 Mn | 17.14 Mn | 17.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.67 Mn |
| Mar 31, 2026 | 14.73 Mn |
| Dec 31, 2025 | 16.82 Mn |
| Sep 30, 2025 | 2.61 Mn |
| Jun 30, 2025 | 2.81 Mn |
| Mar 31, 2025 | 14.55 Mn |
| Dec 31, 2024 | 30.73 Mn |
| Sep 30, 2024 | 16.07 Mn |
| Jun 30, 2024 | 16.42 Mn |
| Mar 31, 2024 | 17.76 Mn |
| Dec 31, 2023 | 18.49 Mn |
| Sep 30, 2023 | 91.30 Mn |
| Jun 30, 2023 | 94.49 Mn |
| Mar 31, 2023 | 87.67 Mn |
| Dec 31, 2022 | 55.88 Mn |
| Sep 30, 2022 | 93.66 Mn |
| Jun 30, 2022 | 96.02 Mn |
| Mar 31, 2022 | 94.18 Mn |
| Dec 31, 2021 | 92.79 Mn |
| Sep 30, 2021 | 69.57 Mn |